Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 4/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | NRP1 | O14786 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | FURIN | P09958 | 5/20 | 0.46 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774670 | 1.00 | EGFR (0.53) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL1738251 | 0.95 | CYP2C19 (0.51) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL1735294 | 0.94 | NPY1R (0.55) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL29774695 | 0.93 | EGFR (0.60) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL1736266 | 0.87 | NPY1R (0.55) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL29794337 | 0.86 | CYP2C19 (0.56) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL30296822 | 0.86 | NOS2 (0.63) | NPY1RNPY2RNPY4RCYP1A2GLA | |
| SCHEMBL29354613 | 0.85 | TERT (0.48) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL29351042 | 0.84 | ERAP2 (0.52) | EGFRNPY1RNPY2RNPY4RCYP1A2 | |
| SCHEMBL29355798 | 0.84 | NPY1R (0.51) | EGFRNPY1RNPY2RNPY4RCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777875-B1 | SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-3548105-B1 | METHOD FOR PRODUCING A PEPTIDE-BASED NANO FIBER STRUCTURE AND A NANO FIBER STRUCTURE THUS OBTAINED | HUMANA MEDICAL S R L (IT) | 2025-03-05 | — | — | EP | disclosed |
| US-12006085-B2 | Fill-finish process for peptide solutions | 3-D MATRIX, LTD. (JP) | 2024-06-11 | — | — | US | disclosed |
| US-11839694-B2 | Compositions and methods for promoting hemostasis and other physiological activities | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3-D MATRIX, LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-2283851-B1 | Compositions for promoting hemostasis | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220324601-A1 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-10-13 | — | — | US | disclosed |
| EP-4049671-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220258900-A9 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-4023240-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | IAPP, NGLY1, VIP | EGFR 1852/4885NPY1R 3582/4885NPY2R 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.